Liv.52 maker bets on new discoveries for growth
The Himalaya Drug Company, the maker of blockbuster liver care drug, Liv.52, is betting on new discoveries to drive its turnover targets over the next three years.business Updated: Aug 14, 2012 23:25 IST
The Himalaya Drug Company, the maker of blockbuster liver care drug, Liv.52, is betting on new discoveries to drive its turnover targets over the next three years.
The company has set a target of doubling its revenues to Rs 2400 crore by the end of 2015 against Rs 1200 crore at the end of 2011-12. “The pipeline for new launches is robust — with over 80 products under development — which will help us reach the target,” said Philipe Haydon, chief executive officer, pharmaceutical division, The Himalaya Drug Company. “These are mainly in the areas of oncology, nutritional support, infectious diseases, diabetes and lifestyle-related disorders.”
Moreover, the company is looking to expand its portfolio of prescription nutri-health products in the next two years by launching 5-6 new variants. These include adult nutrition and nutritional supplements.
The herbal pharmaceutical firm, growing by over 27% year-on-year, is eyeing new markets.
“In India, we are looking to expand into the rural areas,” said Haydon.” Overseas, Asia Pacific is emerging as a powerful market along with expanding into countries like Singapore, Malaysia, and Thailand among others.”
It’s pharmaceutical segment has about 1% share in the Rs 62,000-crore market. The company is setting up new drug categories for ailments including ENT, lifestyle diseases and baby care to boost its marketshare. It currently has 66 brands and 91 stock-keeping units in its portfolio.
The company’s flagship Liv.52 is the only herbal drug to be ranked in the list of top 10 highest-selling drugs in India.